<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="55082"><DrugName>NiK-004</DrugName><DrugSynonyms><Name><Value>NiK-004</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>dual NK-1/NK-2 receptor antagonists (CNS disorders), Brane</Value></Name></DrugSynonyms><CompanyOriginator id="1010152">NiKem Research Srl</CompanyOriginator><CompaniesSecondary><Company id="1010152">NiKem Research Srl</Company><Company id="1032004">Brane Discovery Srl</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1010152" type="Company"><TargetEntity id="4297453699" type="organizationId">NiKem Research Srl</TargetEntity></SourceEntity><SourceEntity id="1032004" type="Company"><TargetEntity id="5035525161" type="organizationId">Brane Discovery Srl</TargetEntity></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="267" type="Action"><TargetEntity id="317" type="Mechanism">Tachykinin NK2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="266" type="Action"><TargetEntity id="316" type="Mechanism">Tachykinin NK1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01432" type="ciTarget"><TargetEntity id="200558287368693" type="siTarget">Substance-P receptor</TargetEntity><TargetEntity id="1139" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01433" type="ciTarget"><TargetEntity id="42129332968653" type="siTarget">Substance-K receptor</TargetEntity><TargetEntity id="-292574261" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="60">Central nervous system disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="266">NK1 receptor antagonist</Action><Action id="267">NK2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2939">CNS modulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N</Code><Name>CENTRAL NERVOUS SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-29T04:07:58.000Z</LastModificationDate><ChangeDateLast>2011-01-03T09:51:45.000Z</ChangeDateLast><AddedDate>2006-03-14T17:21:17.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;It is presumed that &lt;ulink linkID="1032004" linkType="Company"&gt;Brane Discovery&lt;/ulink&gt;, after it was spun off from &lt;ulink linkID="1010152" linkType="Company"&gt;Nikem Research&lt;/ulink&gt; in April 2007 [&lt;ulink linkID="786710" linkType="Reference"&gt;786710&lt;/ulink&gt;], was investigating NiK-004, a series of dual neurokinin -1 and -2 (NK-1/NK-2) receptor antagonists, for the potential treatment of CNS disorders [&lt;ulink linkID="655324" linkType="Reference"&gt;655324&lt;/ulink&gt;], [&lt;ulink linkID="655329" linkType="Reference"&gt;655329&lt;/ulink&gt;], [&lt;ulink linkID="660291" linkType="Reference"&gt;660291&lt;/ulink&gt;]. By March 2006, the project was in lead discovery [&lt;ulink linkID="655324" linkType="Reference"&gt;655324&lt;/ulink&gt;], [&lt;ulink linkID="655329" linkType="Reference"&gt;655329&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By March 2006, candidate compounds had displayed NK-1/NK-2 antagonsim in the high nanomolar range. Compounds had shown manageable liabilites towards P450 isoenzymes and acceptable in vitro pharmacokinetic profiles [&lt;ulink linkID="655324" linkType="Reference"&gt;655324&lt;/ulink&gt;], [&lt;ulink linkID="655329" linkType="Reference"&gt;655329&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In April 2007, NiKem spun off its drug discovery arm as Brane Discovery, an independent pharmaceutical company focused on the development of CNS therapies [&lt;ulink linkID="786710" linkType="Reference"&gt;786710&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2003, NiKem published &lt;ulink linkID="PA2935708" linkType="Patent"&gt;WO-2005000845&lt;/ulink&gt; claiming the use of naphthalene and related heterobicyclic derivatives as NK-1 and NK-2 antagonists.&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1010152">NiKem Research Srl</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="60">Central nervous system disease</Indication><StatusDate>2007-04-23T00:00:00.000Z</StatusDate><Source id="786710" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032004">Brane Discovery Srl</Company><Country id="IT">Italy</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate>2011-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1010152">NiKem Research Srl</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate>2005-04-14T00:00:00.000Z</StatusDate><Source id="655329" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032004">Brane Discovery Srl</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate>2007-04-23T00:00:00.000Z</StatusDate><Source id="660291" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01432"><Name>NK1 receptor</Name><SwissprotNumbers><Swissprot>P14600</Swissprot><Swissprot>P25103</Swissprot><Swissprot>P30547</Swissprot><Swissprot>P30548</Swissprot><Swissprot>Q5DUB1</Swissprot><Swissprot>Q5DUB3</Swissprot><Swissprot>Q98982</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01433"><Name>NK2 receptor</Name><SwissprotNumbers><Swissprot>P05363</Swissprot><Swissprot>P16610</Swissprot><Swissprot>P21452</Swissprot><Swissprot>P30549</Swissprot><Swissprot>P51144</Swissprot><Swissprot>P79218</Swissprot><Swissprot>Q5DUB2</Swissprot><Swissprot>Q64077</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>